Molecular approaches to treatment of hepatocellular carcinoma

Digestive and Liver Disease

Volumn 42, Issue SUPPL. 3, 2010, Pages S264-S272

  Lachenmayer, Anja ^a,b   Alsinet, Clara ^c   Chang, Charissa Y ^a   Llovet, Josep M ^a,c,d  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^c INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^d INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

Clinical trials; Methylation; Molecular pathogenesis; Molecular targeted therapy; Tyrosine kinase inhibitors

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; ANTINEOPLASTIC AGENT; AVE 1642; BETA CATENIN; BEVACIZUMAB; BIIB 022; BRIVANIB; CETUXIMAB; ERLOTINIB; GEFITINIB; GEMCITABINE; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE; OXALIPLATIN; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PROTEIN KINASE B; RAPAMYCIN; RAS PROTEIN; SCATTER FACTOR RECEPTOR; SOMATOMEDIN; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VATALANIB; WNT PROTEIN; DNA METHYLTRANSFERASE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CANCER SURVIVAL; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DNA METHYLATION; DRUG MECHANISM; EPIGENETICS; GASTROINTESTINAL HEMORRHAGE; GENE EXPRESSION; GENE MUTATION; GENETIC ANALYSIS; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER METASTASIS; MOLECULARLY TARGETED THERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; CARCINOMA, HEPATOCELLULAR; DRUG DESIGN; GENETIC EPIGENESIS; GENETICS; LIVER NEOPLASMS; PATHOPHYSIOLOGY;

CARCINOMA, HEPATOCELLULAR; DNA MODIFICATION METHYLASES; DRUG DESIGN; EPIGENESIS, GENETIC; HUMANS; LIVER NEOPLASMS; MICRORNAS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES;

EID: 77953719509     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1590-8658(10)60515-4     Document Type: Article

References (30)

1. El-Serag HB, Rudolph KL Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132:2557-2576.
2. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
3. Bruix J, Sherman M Management of hepatocellular carcinoma. Hepa-tology 2005, 42:1208-1236.
4. Llovet JM, Bruix J Systematic review of randomized trials for unre-sectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003, 37:429-442.
5. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359:378-390.
6. Villanueva A, Newell P, Chiang DY, et al. Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 2007, 27:55-76.
7. Farazi PA, DePinho RA Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006, 6:674-687.
8. Llovet JM, Burroughs A, Bruix J Hepatocellular carcinoma. Lancet 2003, 362:1907-1917.
9. Feitelson MA, Lee J Hepatitis B virus integration, fragile sites, and hepatocarcinogenesis. Cancer Lett 2007, 252:157-170.
10. Vogelstein B, Kinzler KW Cancer genes and the pathways they control. Nat Med 2004, 10:789-799.
11. Chiang DY, Villanueva A, Hoshida Y, et al. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res 2008, 68:6779-6788.
12. Laurent-Puig P, Legoix P, Bluteau O, et al. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology 2001, 120:1763-1773.
13. Llovet JM, Bruix J Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008, 48:1312-1327.
14. Calvisi DF, Ladu S, Gorden A, et al. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology 2006, 130:1117-1128.
15. Hanahan D, Weinberg RA The hallmarks of cancer. Cell 2000, 100:57-70.
16. Fabregat I, Roncero C, Fernandez M Survival and apoptosis: a dysreg-ulated balance in liver cancer. Liver Int 2007, 27:155-162.
17. Minguez B, Tovar V, Chiang D, et al. Pathogenesis of hepatocellular carcinoma and molecular therapies. Curr Opin Gastroenterol 2009, 25:186-194.
18. Farazi PA, Glickman J, Jiang S, et al. Differential impact of telomere dysfunction on initiation and progression of hepatocellular carcinoma. Cancer Res 2003, 63:5021-5027.
19. Zhang C, Li H, Zhou G, et al. Transcriptional silencing of the TMS1/ASC tumour suppressor gene by an epigenetic mechanism in hepatocellular carcinoma cells. J Pathol 2007, 212:134-142.
20. Kondo Y, Shen L, Suzuki S, et al. Alterations of DNA methylation and histone modifications contribute to gene silencing in hepatocellular carcinomas. Hepatol Res 2007, 37:974-983.
21. Viswanathan SR, Powers JT, Einhorn W, et al. Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet 2009, 41:843-848.
22. Llovet JM, Bru C, Bruix J Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999, 19:329-338.
23. Hoshida Y, Nijman SM, Kobayashi M, et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res 2009, 69:7385-7392.
24. Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Nati Cancer Inst 2008, 100:698-711.
25. Villanueva A, Chiang DY, Newell P, et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 2008, 135(6):1972-1983.
26. Newell P, Toffanin S, Villanueva A, et al. Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol 2009, 51:725-733.
27. Ribatti D, Vacca A, Nico B, et al. Angiogenesis and anti-angiogenesis in hepatocellular carcinoma. Cancer Treat Rev 2006, 32:437-444.
28. Zhu AX, Blaszkowsky LS, Ryan DP, et al. Phase II study of gemcita-bine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006, 24:1898-1903.
29. Faivre S, Raymond E, Boucher JY, et al. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open label, multicenter, phase II study. Lancet Oncol 2009, 10:794-800.
30. Sharma S, Kelly TK, Jones PA Epigenetics in cancer. Carcinogenesis 2010, 31(1):27-36.